Company: BDRX
Filing Date: 2025-09-12
Form Type: 424B3
Source: 0001214659-25-013675
Chunk: 10

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-09-12
Form: 424B3
Chunk 10
---
 | £(0.92)m | N/M    |

Biodexa’s
KPIs focus on the key areas of operating results, R&D spend and cash management. These measures provide information on the core R&D
operations. Additional financial and non-financial KPIs may be adopted in due course.

Revenues

Revenue for both
periods was £Nil. The last of the Company’s R&D collaborations concluded in September 2023.

Research and Development

R&D costs for
1H25 and 1H24, analysed by development project indication were as follows:

| Six months ended June 30           |     |  2025 |     |  2024 |
|:-----------------------------------|:----|------:|:----|------:|
|                                    |     | £’000 |     | £’000 |
| eRapa                              |     |       |     |       |
| Familial Adenomatous Polyposis     |     |   251 |     |   175 |
| Non-muscle Invasive Bladder Cancer |     |   127 |     |    95 |
| Total eRapa                        |     |   378 |     |   270 |
| Tolimidone                         |     |       |     |       |
| Type 1 Diabetes                    |     |   270 |     |   383 |
| Total tolimidone                   |     |   270 |     |   383 |
| MTX110 (panobinostat)              |     |       |     |       |
| Diffuse Midline Glioma             |     |     - |     |     - |
| Recurrent Glioblastoma             |     |    14 |     |   360 |
| Medulloblastoma                    |     |     - |     |     - |
| Total MTX110 (panobinostat)        |     |    14 |     |   360 |
| Other preclinical                  |     |     1 |     |   104 |
| R&D overheads                      |     | 1,002 |     | 1,072 |
| Total R&D                          |     | 1,665 |     | 2,189 |

R&D costs in
1H25 reduced by £0.52 million, or 24%, to £1.67 million compared with £2.19 million in 1H